Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza
Sponsor: GlaxoSmithKline
Terminated
The study was stopped early due to lack of enrollment.
A PHASE2 clinical study on Virus Diseases, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 18 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 13 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2019 — Dec 2020 [monthly]
Terminated PHASE2
-
Aug 2018 — Sep 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — Jan 2018 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .